Synthesis and structure–Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family-Reference-Cited by-同舟云学术

Synthesis and structure–Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-piperidinyl)-piperazine family

Published:2002-03 Issue:5 Volume:12 Page:795-798
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

McCombie Stuart W,Lin Sue-Ing,Tagat Jayaram R,Nazareno Dennis,Vice Susan,Ford Jennifer,Asberom Theodros,Leone Daria,Kozlowski Joseph A,Zhou Guowei,Ruperto Vilma B,Duffy Ruth A,Lachowicz Jean E

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference12 articles.

1. The Cholinergic Hypothesis of Geriatric Memory Dysfunction

2. Lipophilic muscarinic M2 antagonists as potential drugs for cognitive disorders

3. Chapter 3. Recent Advances in the Design and Characterization of Muscarinic Agonists and Antagonists

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enantiomerically pure piperazines via NaBH4/I2 reduction of cyclic amides;Tetrahedron: Asymmetry;2017-01

2. Bioisosteric Replacement and Related Analogs in the Design, Synthesis and Evaluation of Ligands for Muscarinic Acetylcholine Receptors;Medicinal Chemistry;2014-04

3. Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M5-Preferring Muscarinic Receptor Orthosteric Antagonists;Journal of Medicinal Chemistry;2013-02-18

4. ChemInform Abstract: Synthesis and Structure-Activity Relationships of M2-Selective Muscarinic Receptor Ligands in the 1-[4-(4-Arylsulfonyl)phenylmethyl]-4-(4-piperidinyl)-piperazine Family.;ChemInform;2010-05-21

5. Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease;Current Pharmaceutical Design;2005-10-01